Cara Therapeutics (CARA) : Traders are negative on Cara Therapeutics (CARA), as it has 7.2% of short positions outstanding compared to its float. The total shorts have reduced by -204,114 shares, which is a -11.8% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,1,733,007 to 1,528,893 shares. While the daily trading volume of the stock is 762,993, there are 2 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Cara Therapeutics (NASDAQ:CARA): The stock opened at $5.99 on Wednesday but the bulls could not build on the opening and the stock topped out at $6.09 for the day. The stock traded down to $5.45 during the day, due to lack of any buying support eventually closed down at $5.56 with a loss of -7.18% for the day. The stock had closed at $5.99 on the previous day. The total traded volume was 969,468 shares.
In a related news,The officer (VP-Research & Development) of Cara Therapeutics, Inc., Menzaghi Frederique Ph.D. sold 6,000 shares at $9 on April 20, 2016. The Insider selling transaction had a total value worth of $54,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.